Genmab presents updated Phase 2 data for petosemtamab plus pembrolizumab in first-line head and neck cancer at ESMO

Genmab presented updated Phase 2 data for petosemtamab plus pembrolizumab in first-line PD-L1-positive recurrent/metastatic head and neck cancer at the ESMO Congress 2026.

Detected & updated continuously · Source: Nebula